Italia markets closed

Ekso Bionics Holdings, Inc. (0IFR.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,5000-0,3620 (-19,44%)
Alla chiusura: 03:23PM BST
Schermo intero
Chiusura precedente1,8620
Aperto1,6980
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno1,6980 - 1,6980
Intervallo di 52 settimane1,6980 - 1,6980
Volume40
Media VolumeN/D
Capitalizzazione106,474M
Beta (5 anni mensile)1,92
Rapporto PE (ttm)N/D
EPS (ttm)-0,9260
Prossima data utili27 lug 2022 - 01 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Ekso Bionics Reports First Quarter 2022 Results

    RICHMOND, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2022. Recent Highlights and Accomplishments Reported revenue of $2.6 million in the first quarter of 2022Strong cash position of $36.2 million at March 31, 2022Booked a total of 23 EksoNR units in the first quarter of 2022Secured three mult

  • GlobeNewswire

    Ekso Bionics to Report First Quarter 2022 Financial Results on April 28

    RICHMOND, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2022 after the close of trading on Thursday, April 28, 2022. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. A live webca

  • GlobeNewswire

    Ekso Bionics Reports Fourth Quarter and Year End 2021 Results

    RICHMOND, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2021. Recent Highlights and Accomplishments Reported record revenue of $4.1 million in the fourth quarter of 2021Achieved gross margin of approximately 59% in the fourth quarter of 2021Booked a total of 30 EksoNR units in the f